Business Context and Reporting Period
Company: LeMaitre Vascular, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2009
Business Overview: LeMaitre Vascular develops, manufactures, and markets medical devices and implants for vascular surgery. The company operates in a single segment with principal product lines including thoracic and abdominal stent grafts, anastomotic clips, and vascular grafts. Operations are headquartered in Burlington, Massachusetts, with international offices in Germany, Italy, and Japan.
Key Financial Metrics
| Metric (in thousands) | Q1 2009 | Q1 2008 |
|---|---|---|
| Net Sales | $11,348 | $11,847 |
| Gross Profit | $8,266 | $8,489 |
| Gross Margin | 72.8% | 71.7% |
| Operating Loss | $(1,566) | $(2,586) |
| Net Loss | $(1,881) | $(2,564) |
| Net Loss Per Share (Basic & Diluted) | $(0.12) | $(0.17) |
| Cash and Cash Equivalents | $14,093 | $5,444 |
| Marketable Securities | $3,171 | $5,359 |
| Total Current Assets | $33,042 | $37,116 |
| Total Current Liabilities | $5,121 | $6,933 |
| Long-Term Debt | $79 | $78 |
| Net Cash Used in Operating Activities | $(2,306) | $(4,055) |
Material Changes vs. Prior Period
- Revenue Decline: Net sales decreased 4% year-over-year to $11.3 million. The decline was primarily driven by a $0.6 million negative impact from foreign currency exchange rate fluctuations (stronger U.S. dollar), a $0.4 million decrease in sales to international distributors, and a $0.4 million decrease in AlboGraft sales to Edwards Lifesciences during the wind-down of their distribution agreement.
- Margin Expansion: Despite lower sales, gross margin improved by 1.1 percentage points to 72.8%. This was due to higher average selling prices, increased margin contribution from the Powerlink product line and Biomateriali subsidiary, and reduced sales to lower-margin European distributors.
- Restructuring Charges: Operating expenses included a significant $1.8 million restructuring charge in Q1 2009, compared to $0.6 million in Q1 2008. The 2009 charge was related to the termination of the AlboGraft distribution agreement with Edwards Lifesciences.
- Operating Loss Improvement: The operating loss narrowed to $1.6 million from $2.6 million in the prior year, largely due to a 29% reduction in sales and marketing expenses ($4.1 million vs. $5.8 million) and lower impairment charges.
- Cash Flow: Net cash used in operating activities improved significantly to $2.3 million from $4.1 million in the prior year, driven by a lower net loss and reduced cash outflows for working capital.
Guidance, Outlook, and Risks
- Outlook: Management expects to fund operations, capital expenditures, and deferred acquisition payments for at least the next 12 months using existing cash, cash equivalents, and marketable securities ($17.3 million total as of March 31, 2009). However, the company may require additional funds for future acquisitions.
- Credit Facility: The company maintains a $10.0 million revolving line of credit with no outstanding balance. The facility matures in August 2009. Management noted that due to the current economic environment and credit market volatility, there is no assurance the facility will be renewed on acceptable terms.
- Foreign Currency Risk: Approximately 41% of net sales are denominated in foreign currencies (primarily Euro and Yen). Management warned that the negative impact of currency fluctuations observed in Q1 2009 may continue into the second quarter.
- Contractual Breach: The company failed to meet minimum purchase requirements under an exclusive distribution agreement with Endologix, Inc. by $0.3 million in Q1 2009. While the manufacturer has the right to terminate the agreement, no notice of default had been issued as of March 31, 2009.
- Impairment: The company recorded a $0.1 million impairment charge for patents in the endovascular portfolio where product development milestones were likely to be missed.
Investor Verification Checklist
- Credit Facility Renewal: Verify the status of the $10 million revolving credit line maturing in August 2009 and the company's ability to secure refinancing given current market conditions.
- Endologix Agreement: Monitor for any notice of default or termination regarding the breach of minimum purchase requirements with Endologix, Inc.
- Currency Exposure: Assess the ongoing impact of foreign exchange rates on revenue and operating expenses, particularly given the 41% exposure to non-U.S. currencies.
- Restructuring Completion: Confirm the full execution and cost realization of the $1.8 million restructuring charge related to the Edwards Lifesciences distribution termination.
- Product Pipeline: Review the status of the UNITE clinical trial and other R&D projects, as the company recorded impairments for patents failing to meet development milestones.